31LBA MOST – My Own Specific Therapy – A multicenter, randomized, open-label, phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors: preliminary results from the everolimus and sorafenib cohorts. (September 2015) - Toulmonde, M.; Le Tourneau, C.; Cropet, C.; Italiano, A.; Bertucci, F.; Ray-Coquard, I.; Tredan, O.; Cassier, P.; Seigne, C.; De la Fouchardiere, C.; Flechon, A.; Desseigne, F.; et al.